WO2013016741A1 - Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement - Google Patents

Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement Download PDF

Info

Publication number
WO2013016741A1
WO2013016741A1 PCT/ZA2011/000053 ZA2011000053W WO2013016741A1 WO 2013016741 A1 WO2013016741 A1 WO 2013016741A1 ZA 2011000053 W ZA2011000053 W ZA 2011000053W WO 2013016741 A1 WO2013016741 A1 WO 2013016741A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
dietary supplement
berberine
weight loss
fat
Prior art date
Application number
PCT/ZA2011/000053
Other languages
English (en)
Inventor
Conrad Anton SMITH
Original Assignee
Smith Conrad Anton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Conrad Anton filed Critical Smith Conrad Anton
Priority to PCT/ZA2011/000053 priority Critical patent/WO2013016741A1/fr
Publication of WO2013016741A1 publication Critical patent/WO2013016741A1/fr
Priority to ZA2014/01237A priority patent/ZA201401237B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • Insulin is an important controller of organic metabolism. It acts both directly and indirectly on most bodily tissues. Its actions can be divided into two broad categories:
  • the invention is based on the proposition that aspects of fat breakdown and use for providing energy are enhanced in the absence of insulin. This can occur normally between meals when secretion of insulin is minimal but the effect becomes extreme in diabetes mellitus when secretion of insulin is almost absent. When this happens, the aforementioned effects of insulin causing the production and storage of fat are reversed.
  • a dominant effect is that the enzyme hormone-sensitive lipase in the fat cells become strongly activated. This causes hydrolysis of stored triglycerides, releasing large quantities of fatty acids and glycerol from the adipose tissue into the circulating blood. The net effect or result is significant weight-loss.
  • a goal in this respect is a strategy in which the insulin level is lowered to a value which is still healthy but which does not promote fat deposition and fat storage, thereby counteracting insulin's obesity promoting effects.
  • the invention consists of a combination of naturally derived compounds and plant extracts that display complementary and synergistic pharmaceutical effects, all of which have been proven to be useful for the treatment or alleviation of insulin resistance.
  • the mode of action is via a triple-action mechanism, which optimises catabolic metabolism by lowering insulin levels and increasing the usage of fat for energy purposes, thereby assisting with weight loss.
  • the invention provides a dietary supplement which includes, in combination, berberine, banaba leaf and inositol.
  • LDLR low-density lipoprotein receptors
  • InsR insulin receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement, ledit complément alimentaire contenant de la berbérine, des feuilles de banaba et de l'inositol.
PCT/ZA2011/000053 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement WO2013016741A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/ZA2011/000053 WO2013016741A1 (fr) 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement
ZA2014/01237A ZA201401237B (en) 2011-07-22 2014-02-19 Dietary supplement for use in a weight loss program

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ZA2011/000053 WO2013016741A1 (fr) 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement

Publications (1)

Publication Number Publication Date
WO2013016741A1 true WO2013016741A1 (fr) 2013-01-31

Family

ID=44543898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2011/000053 WO2013016741A1 (fr) 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement

Country Status (2)

Country Link
WO (1) WO2013016741A1 (fr)
ZA (1) ZA201401237B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2923701A1 (fr) 2014-03-27 2015-09-30 Neopharmed Gentili S.r.l. Formulation pour le traitement et le contrôle du syndrome métabolique et des troubles corrélés
ITUA20163025A1 (it) * 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012706A1 (fr) * 1991-01-23 1992-08-06 University Of Virginia Patents Foundation Procede permettant de reduire des taux eleves de glycemie chez l'homme
WO2002094018A1 (fr) * 2001-05-23 2002-11-28 Insmed Incorporated Compositions a base de d-chiro inositol et de composes hypolipidemiants et methodes therapeutiques les utilisant
WO2007090289A1 (fr) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinaisons d'extraits botaniques pour favoriser la santé cardio-vasculaire
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
US7476406B1 (en) * 2004-05-17 2009-01-13 Nse Products, Inc. Multifaceted weight control system
EP2070926A1 (fr) * 2006-09-30 2009-06-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Dérivés de 13,13a-dihydroberbérine, leur composition pharmaceutique et leurs utilisations
WO2011061749A2 (fr) * 2009-11-19 2011-05-26 Ganga Raju Gokaraju Agents dérivés d'holoptelea integrifolia et leurs compositions destinées à lutter contre le syndrome métabolique et les maladies associées

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012706A1 (fr) * 1991-01-23 1992-08-06 University Of Virginia Patents Foundation Procede permettant de reduire des taux eleves de glycemie chez l'homme
WO2002094018A1 (fr) * 2001-05-23 2002-11-28 Insmed Incorporated Compositions a base de d-chiro inositol et de composes hypolipidemiants et methodes therapeutiques les utilisant
US7476406B1 (en) * 2004-05-17 2009-01-13 Nse Products, Inc. Multifaceted weight control system
WO2007090289A1 (fr) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinaisons d'extraits botaniques pour favoriser la santé cardio-vasculaire
EP2070926A1 (fr) * 2006-09-30 2009-06-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Dérivés de 13,13a-dihydroberbérine, leur composition pharmaceutique et leurs utilisations
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
WO2011061749A2 (fr) * 2009-11-19 2011-05-26 Ganga Raju Gokaraju Agents dérivés d'holoptelea integrifolia et leurs compositions destinées à lutter contre le syndrome métabolique et les maladies associées

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2923701A1 (fr) 2014-03-27 2015-09-30 Neopharmed Gentili S.r.l. Formulation pour le traitement et le contrôle du syndrome métabolique et des troubles corrélés
ITUA20163025A1 (it) * 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
WO2017187375A1 (fr) * 2016-04-29 2017-11-02 Sochim International S.P.A. Composition pour le traitement du syndrome des ovaires polykystiques
EP3448370B1 (fr) 2016-04-29 2020-10-21 Sochim International SpA Composition pour le traitement du syndrome des ovaires polykystiques

Also Published As

Publication number Publication date
ZA201401237B (en) 2015-08-26

Similar Documents

Publication Publication Date Title
Chantre et al. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity
AU2002364213B2 (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US20120148685A1 (en) Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
KR101069502B1 (ko) 비만 및 당뇨병 개선용 경구용 조성물
CN104366510B (zh) 茶叶茶氨酸保健食品组合物及其制备方法
EP1744732A2 (fr) Composition nutritionnelle destinee a augmenter l'absorption de creatine dans les muscles squelettiques
Hoffman et al. Thermogenic effect of an acute ingestion of a weight loss supplement
HUE034393T2 (en) Increasing the bioavailability of a drug in naltrexone therapy
US10543241B2 (en) Methods and materials for reducing multiple risk factors associated with the metabolic syndrome
US8349373B1 (en) Dietary supplement for use in a weight loss program
US8420131B2 (en) Composition for obesity treatment
WO2013016741A1 (fr) Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement
WO2004085462A2 (fr) Procede et composition pour faire baisser le taux de ghreline
WO2005041995A1 (fr) Inhibiteur de l'activite de l'alpha-glucosidase
JP6650053B2 (ja) ブチリデンフタリドの用途
EP3860615B1 (fr) Composition orale comprenant de la b-escine et utilisation associée
WO2013016742A1 (fr) Composition utilisable dans le cadre d'un traitement contre l'obésité
CN111686239A (zh) 抗真菌化合物的应用
JP2020535222A (ja) 満腹および／または食欲に関与するペプチドレベルの調節による体重管理のための組成物
KR20100028616A (ko) 비만 개선용 경구 조성물
BATUBARA et al. The potency of Berastagi sweet orange (Citrus sinensis) peel extract for obesity treatment: An experimental study in male rats
JP2019054788A (ja) 推算糸球体濾過量および腎機能の低下予防・抑制用組成物
JP2019055938A (ja) ナトリウム排泄促進用及び／又はナトリウム吸収抑制用組成物
WO2008107910A2 (fr) Utilisation d'extraits de caralluma dans l'inhibition de l'adipogenèse et procédé d'inhibition de l'adipogenèse
DOSAY-AKBULUT et al. Afyon Kocatepe Üniversitesi Fen ve Mühendislik Bilimleri Dergisi

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11751783

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751783

Country of ref document: EP

Kind code of ref document: A1